Skip to the content
Pictorlogo darklogo light
  • Human Health
    • SARS-CoV-2 Antibodies
  • Animal Health
    • Johne’s Disease / MAP
    • Mycoplasma bovis
  • Technology
    • Multiplex Solution
    • eIFUs & Downloads
  • About
    • About Pictor
    • Our People
    • Our Board
  • News
  • Contact Us
  • Investors
Pictor
  • Human Health
    • SARS-CoV-2 Antibodies
  • Animal Health
    • Johne’s Disease / MAP
    • Mycoplasma bovis
  • Technology
    • Multiplex Solution
    • eIFUs & Downloads
  • About
    • About Pictor
    • Our People
    • Our Board
  • News
  • Contact Us
  • Investors
Pictor
  • Human Health
    • SARS-CoV-2 Antibodies
  • Animal Health
    • Johne’s Disease / MAP
    • Mycoplasma bovis
  • Technology
    • Multiplex Solution
    • eIFUs & Downloads
  • About
    • About Pictor
    • Our People
    • Our Board
  • News
  • Contact Us
  • Investors
7 February 2024
Animal HealthHuman HealthPRESS RELEASETechnology

Disrupting a market, not creating one

Article from the “CAFFEINE” – The daily for New Zealand’s Startups

What kiwi founders could learn from the turnaround at Auckland biotech company Pictor under new CEO Jamie Platt.
Click here for the full article
Categories
  • Animal Health (3)
  • Human Health (5)
  • PRESS RELEASE (6)
  • Technology (2)
Tags

Awanui Group Bovine Clinical Trials CoVID-19 Investment k1w1 K One W One Marko Bogoievski Mobility Health PRESS RELEASE SARS-CoV-2 Scienion Sir Stephen Tindall Tasso

Head Office
Pictor Ltd.

24 Balfour Road, Parnell, Auckland 1052, New Zealand


NZ +64 9 3090950

info@pictordx.com

Pictor products are manufactured in ISO 13485:2016 certified facilities.

3770 Tansy St, Suite #101, San Diego, CA 92121, United States

US +1-800-641-1096

Pictor products are manufactured in ISO 13485:2016 certified facilities.

  • Linkedin
  • Facebook
  • Twitter
  • Instagram

© 2022 Pictor Limited, All Rights Reserved.

Site by Memory Partners

Back to top